Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course

Table 2 Univariate Cox progression-free survival analyses of various clinical parameters

	Univariate analysis
Clinical Parameters	P-value	HR	95%CI
sunitinib vs. sorafenib	0.341	1.585	0.614-4.096
clear cell vs. papillary	0.087	2.841	0.860-9.379
nephrectomy: yes vs. no	0.620	0.725	0.203-2.590
pretreatment: yes vs. no	0.205	0.500	0.171-1.459
previous TKI: yes vs. no	0.380	0.510	0.113-2.293
previous IFN: yes vs. no	0.056	0.284	0.078-1.033
number of lesions: 1–2 vs. 3 ≥	0.056	3.046	0.971-9.559
lung metastasis: only vs. others	0.359	0.552	0.155-1.967
bone metastasis: no vs. yes	0.927	0.942	0.264-3.365
liver metastasis: no vs. yes	0.004	7.672	1.891-31.130

ISSN: 1471-2407